In:
Frontiers in Oncology, Frontiers Media SA, Vol. 10 ( 2020-11-30)
Abstract:
Extranodal natural killer T cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma with invariable infection of lymphoma cells with Epstein-Barr virus (EBV), and the presence of EBV-DNA in the blood is a well-known prognosticator. However, there is no consensus on which blood compartment is more optimal for predicting survival outcomes. Methods We analyzed 60 patients who were newly diagnosed with ENKTL from a prospectively collected database. EBV-DNA was measured in the whole-blood (WB) and plasma at the time of diagnosis and after treatment completion. Results EBV-DNA was detected in pre-treatment WB and plasma in 37 (61.7%) and 23 (38.3%) patients, respectively. The presence of pre-treatment plasma EBV-DNA was significantly associated with advanced stage while presence of WB EBV-DNA did not. Positivity of pre-treatment plasma-EBV, but not WB EBV-DNA, was independently associated with poor PFS (HR, 4.22;95% CI, 1.79–9.97; P =0.001) and OS (HR, 8.38; 95% CI, 3.03–23.19; P & lt;0.001) in the multivariate analysis. After treatment completion, positivity of plasma-EBV was independently associated with poor PFS (HR, 9.41; 95% CI, 2.27–39.02; P =0.002) and OS (HR, 32.38; 95% CI, 3.25–322.56; P =0.003), whereas no significant association was observed between WB-EBV status and survival outcomes. Conclusions Our results suggest that EBV-DNA in the plasma has better prognostic values than WB in patients with ENKTL.
Type of Medium:
Online Resource
ISSN:
2234-943X
DOI:
10.3389/fonc.2020.594692
DOI:
10.3389/fonc.2020.594692.s001
DOI:
10.3389/fonc.2020.594692.s002
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2020
detail.hit.zdb_id:
2649216-7
